Novo Nordisk

Novo Nordisk to expand R&D center in China

Tuesday, September 25, 2012 09:58 AM

Novo Nordisk, a Denmark-based biopharmaceutical company and the first multinational company to open a research center in China in 1997, is reaffirming its long-term commitment to the country by investing an additional $100 million to expand its state-of-the-art science facilities in Beijing.

More... »

Regulus Therapeutics appoints Bruce Carter to board of directors

Wednesday, May 2, 2012 04:38 PM

Regulus Therapeutics, a biopharmaceutical company focused on medicines targeting microRNAs, has appointed Bruce Carter, Ph.D., to its board of directors.

More... »

Novo Nordisk licenses Caisson Biotech drug delivery tech

Wednesday, May 2, 2012 11:33 AM

Caisson Biotech, a subsidiary of Heparinex, has entered into a development and license agreement with Novo Nordisk, a global healthcare company based in Denmark.

More... »

Novo Nordisk plans 15% expansion of U.S. work force

Friday, April 27, 2012 01:36 PM

Novo Nordisk, a global healthcare company headquartered in Denmark, is planning a nearly 15% expansion of its U.S. work force in 2012.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Novo Nordisk establishes type I diabetes R&D center in Seattle

Wednesday, January 25, 2012 09:07 AM

Denmark-based Novo Nordisk will establish a type I diabetes R&D center in Seattle, Wash.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

Biogen, Novo Nordisk collaborate with Adimab

Tuesday, August 30, 2011 02:36 PM

Adimab has initiated two independent collaborations with Biogen Idec and Novo Nordisk.

More... »

The CenterWatch Monthly, August 2011

Monday, August 1, 2011 08:26 AM

Sponsors target new areas to speed cycle times

Biopharmaceutical company executives struggle to find ways of shortening drug development cycle time. Sponsors place a high priority on accelerating cycle time to help improve R&D productivity, yet median cycle times, according to analysis of FDA and industry data, increased by nearly 15% between 1994 and 2009, from 77.3 to 81.9 months. Executives say the greatest challenge to reducing cycle time is the large, phase III clinical trial, which has become more complex. Yet overall, these executives say the most promising areas for improving cycle times are...

More... »

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

More... »